NELL1
- Aliases
-
- NEL-like protein 1
- NELL1
- NRP1
- Nel-related protein 1
- Protein kinase C-binding protein NELL1
- nel-like 1
- Description
- NELL1 is a cytoplasmic protein that contains epidermal growth factor (EGF)-like repeats. The encoded heterotrimeric protein may be involved in cell growth regulation and differentiation.
Attributes
- QA State
- Accepted
- Type
- Genomic
- HGNC Name
- NELL1
- Certifications
-
- None
- QA State for Esophagus
- Accepted
Organ-Specific Notes
Esphageal adenocarcinoma risk in Barrett's esophagus is increased 30- to 125- fold versus the general population. Among all Barrett's esophagus patients neoplastic progression occurs only once per 200 patient-years. Molecular markers (individual or in panel) would be useful to risk-stratify patients for more efficient surveillance endoscopy and to improve the early detection of progression.
Performance Comment
Promoter hypermethylation of NELL1 occurs early during Barrett's-associated esophageal neoplastic progression, and is a potential biomarker of poor prognosis in early-stage esophageal adenocarcinoma. Studies are ongoing.
Supporting Study Data
Barretts Esophagus Methylation Profiles
Study phase on the esophagus: 3
We propose a nested case-control study of biomarkers in the setting of BE. By bringing together research institutions with large populations of patients with BE, we will perform a multi-center study of FISH and hypermethylation markers as possible prognostic factors in BE. The centers will select from their cohorts who have progressed to HGD or to adenocarcinoma of the esophagus ("progressors"), and who also donated samples prior to the development of cancer, when their histology was felt to be benign. These subjects will be compared to individuals who have been under endoscopic surveillance, but who have not progressed to HGD or EAC ("non-progressors"). Using this approach, we hope to identify promising markers for risk stratification in BE. We expect to be able to make successful application for a prospective study of markers identified in this case-control study.
View ProtocolDecision rule: PMID:17452981
Barretts Esophagus Methylation Profiles
Study phase on the esophagus: 3
We propose a nested case-control study of biomarkers in the setting of BE. By bringing together research institutions with large populations of patients with BE, we will perform a multi-center study of FISH and hypermethylation markers as possible prognostic factors in BE. The centers will select from their cohorts who have progressed to HGD or to adenocarcinoma of the esophagus ("progressors"), and who also donated samples prior to the development of cancer, when their histology was felt to be benign. These subjects will be compared to individuals who have been under endoscopic surveillance, but who have not progressed to HGD or EAC ("non-progressors"). Using this approach, we hope to identify promising markers for risk stratification in BE. We expect to be able to make successful application for a prospective study of markers identified in this case-control study.
View ProtocolDecision rule: PMID:17452981
Esophagus-Specific Protocols
- No organ-level protocols specified for esophagus.
Esophagus-Specific Publications
- No organ-level publications were listed for esophagus.
Esophagus-Specific Resources
- No organ-level resources were given for esophagus.
- A multicenter, double-blinded validation study of methylation biomarkers for progression prediction in Barrett's esophagus.
- Hypermethylation of the nel-like 1 gene is a common and early event and is associated with poor prognosis in early-stage esophageal adenocarcinoma.
- Three-tiered risk stratification model to predict progression in Barrett's esophagus using epigenetic and clinical features.